Today's article highlights the performance of the munKNEE Psychedelic Drug Stocks Index which tracks six (6) largest psychedelic stocks researching the treatment of mental illnesses based on the use of ten (10) different psychedelic substances (read 10 Psychedelic Substances And The 36 Companies Researching Them), and have market capitalizations in excess of $50M.

Below are the performances of the 6 constituents last week, in descending  order and in the past 3 weeks:

1. GH Research (GHRS): UP 0.5% last week; DOWN 20.7% in past 3 weeks
   • Is focused on developing 5-MeO-DMT therapies for the treatment of patients with Treatment-Resistant Depression.
2. Mind Medicine (MNMD): DOWN 7.0% last week; DOWN 4.5% in past 3 weeks 
   • Is focused on discovering, developing, and deploying therapies to address addiction and mental illness development.
3. Seelos (SEEL): DOWN 12.5% last week; DOWN 35.2% in past 3 weeks 
   • Is focused on developing products for the treatment of Central Nervous System disorders and other rare disorders.
4. Atai (ATAI): DOWN 13.6% last week; DOWN 24.8% in past 3 weeks
   • Is focused on acquiring and developing treatments that lead to paradigm shifts in the mental health space.
5. Compass Pathways (CMPS): DOWN 14.3% last week; DOWN 24.8% in past 3 weeks
   • Is focused on the development of psilocybin therapy for people with Treatment-Resistant Depression.
6. Cybin (CYBN): DOWN 21.9% last week; DOWN 13.9% in past 3 weeks
   • Is focused on utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches, and treatment regimens for psychiatric disorders.

In total, the Index went DOWN 7.6% last week, and is now DOWN 21.7% in the last 3 weeks.

Six (6) other psychedelic companies (see details here) are primarily focused on the development, expansion, and operation of ketamine-assisted therapy (KAT) clinics hoping to capitalize on the massive commercial opportunity that exists to treat the two billion people worldwide who suffer from chronic pain, addiction, substance abuse withdrawal, and depression. All are highly speculative investments and penny stocks with tiny market capitalization. They are as follows, in alphabetical order:

1. Awakn Life Sciences Corp.  (NEO: AWAKN|OTCQB: AWKNF);
2. Delic Corp. (CSE: DELC|OTCQB: DELCF);
3. Field Trip Health and Wellness Ltd. (TSXV: FTHW|OTCQB: FTHWF);
4. Numinus Wellness Inc. (TSX: NUMI|OTCQX: NUMIF);
5. Revitalist Lifestyle and Wellness Ltd. (CSE: CALM|OTCQB: RVLWF);
6.  Universal Ibogaine Inc. (TSXV: IBO|OTCQB: IBOGF)

The above psychedelic-assisted therapy clinic stocks went DOWN 11.9%, on average, last week and are DOWN 21.2% in the past 3 weeks.

More By This Author:

Largest Psychedelic Stocks -7.6% This Week; Now -21.7% This Month
Cannabis Category Performances Ranged From +0.5% To -17% Last Week
Largest Plant-Based Food Stock Collapse Continues: DOWN 8% This Week